Renal Function–Based Dosing of Sitagliptin in Type 2 Diabetes

Assessment of Renal Function

Renal function must be evaluated before starting sitagliptin and reassessed periodically because dose modification is required according to kidney function 1, 2.

Dosing Recommendations by Level of Renal Impairment

In adults with moderate chronic kidney disease (estimated creatinine clearance 30–49 mL/min), a reduced dose of *50 mg once daily* of sitagliptin achieves plasma exposure comparable to the standard 100 mg dose in patients with normal renal function 1, 2.

In adults with severe chronic kidney disease (estimated creatinine clearance < 30 mL/min) or end‑stage renal disease requiring dialysis, a further reduced dose of *25 mg once daily* of sitagliptin is recommended 1, 2.

Prescribing Accuracy

In United Kingdom clinical practice, *41 %* of patients with renal impairment received an inappropriately high sitagliptin dose (100 mg daily) despite the need for dose reduction 1, 2.

Safety Overview (Cited Evidence)

Clinical trials cited by Kidney International demonstrated that the renal‑adjusted doses (50 mg for moderate impairment and 25 mg for severe impairment) provide effective glycemic control with HbA1c reductions of approximately 0.6–0.8 % 1, 2.

The same studies reported a markedly lower incidence of hypoglycemia with sitagliptin (4.6–6.2 %) compared with sulfonylureas (17–23 %) in patients with renal impairment 1, 2.